Mucosal melanoma (MM) is a rare and aggressive form of melanoma that arises in the mucous membranes of the nasal cavity, sinuses, oral cavity, pharynx, and other areas of the head and neck. Unlike the more common cutaneous melanoma, MM is not linked to UV exposure and lacks a clearly defined environmental cause. Due to its occurrence in concealed anatomical locations, it is often diagnosed at a late stage, contributing to its poor prognosis. MM is staged differently from cutaneous melanoma, as the American Joint Committee on Cancer (AJCC) does not apply the traditional TNM (Tumor, Node, Metastasis) system. Instead, staging is based on disease spread: Stage I is localized to the mucosal surface; Stage II involves deeper local invasion without lymph node or distant spread; Stage III indicates regional spread to nearby lymph nodes or deeper tissues; and Stage IV represents distant metastasis to organs such as the lungs, liver, or brain. Alarmingly, most cases are identified at Stage III or IV, complicating treatment and reducing the likelihood of favorable outcomes.

Mucosal melanoma differs significantly from cutaneous melanoma in that it is not linked to ultraviolet (UV) radiation or sun exposure; instead, its origins are less clearly understood. However, several risk factors have been identified through clinical observations and research. Age is a significant factor, with mucosal melanoma being most prevalent in individuals over 50 years old, suggesting that cumulative cellular changes over time may contribute to its development. Gender also appears to play a role, with a slightly higher incidence observed in men, although the reasons for this disparity are not fully understood. People with darker skin tones are at an increased risk, possibly due to biological differences in melanin distribution or mucosal tissue susceptibility. Chronic inflammation or persistent irritation in the mucous membranes such as in the oral cavity or nasal passages has been associated with a heightened risk, likely due to prolonged cellular stress and turnover in these areas. Human papillomavirus (HPV) infection, which is already known to be linked to other mucosal cancers (like cervical or oropharyngeal cancers), has also been suggested as a potential risk factor, though the evidence is still emerging. Lifestyle habits such as smoking and heavy alcohol use may further increase the risk, particularly for oral mucosal melanoma, by contributing to chronic mucosal damage and carcinogenic exposure. Additionally, genetic mutations play a crucial role; mutations in oncogenes such as KIT, NRAS, and occasionally BRAF have been identified in mucosal melanoma cases. These mutations can drive uncontrolled cell growth and malignancy, similar to mechanisms in other cancer types, although the mutation patterns differ from those commonly seen in cutaneous melanoma. Overall, while the precise cause of mucosal melanoma remains elusive, a combination of genetic, biological, environmental, and lifestyle factors appears to contribute to its pathogenesis.

Mucosal melanoma presents with a range of symptoms that vary depending on the tumors location, and because these symptoms are often vague or mimic more common, benign conditions, diagnosis is frequently delayed. In cases where the melanoma develops in the nasal cavity or sinuses, patients may experience persistent nasal congestion or blockage unrelated to allergies, recurrent nosebleeds (epistaxis), blood-streaked mucus, loss of smell (anosmia), facial pain, swelling, numbness, or a noticeable mass within the nasal passages. When the disease affects the oral cavity, it may manifest as a darkly pigmented or non-pigmented mass on the gums, palate, or tongue, accompanied by pain, spontaneous bleeding, gum swelling, loose teeth, or difficulty swallowing (dysphagia). In the throat or laryngeal region, symptoms may include persistent hoarseness or voice changes, chronic sore throat, and, in advanced stages, difficulty breathing due to airway obstruction. As the disease progresses and metastasizes, more generalized or systemic symptoms may appear, such as swollen lymph nodes in the neck, unexplained weight loss, persistent fatigue, and pain in distant organs like the lungs, liver, or brain. The subtlety and non-specific nature of these early signs contribute significantly to the challenge of early detection and effective treatment.

Diagnosing mucosal melanoma is particularly challenging due to its rarity and the non-specific nature of its symptoms, which often leads to misdiagnosis or delayed identification. A comprehensive diagnostic process is essential to accurately confirm the disease and determine its extent. The first step typically involves a physical examination, during which a physician carefully inspects the mouth, nasal passages, throat, and neck for any unusual growths, discolorations, or masses. If an abnormal lesion is found, a biopsy is performed this involves removing a small tissue sample from the suspicious area for microscopic analysis to confirm the presence of melanoma cells. Once a diagnosis is established, various imaging tests are used to evaluate the tumors size, local invasion, and potential spread to other areas. These include CT scans and MRI for detailed views of soft tissues and structural involvement, PET scans to detect metastases in distant organs, and X-rays to assess possible bone involvement. Additionally, genetic testing is conducted to identify mutations in genes such as BRAF, KIT, and NRAS, which not only provide insight into the tumors molecular profile but also guide treatment decisions, particularly the suitability of targeted therapies. This multi-step diagnostic approach is critical for accurate staging and the development of an effective treatment plan.

Treatment for mucosal melanoma is complex and tailored to the individual based on the tumors size, location, and stage at diagnosis. Surgery is typically the primary treatment, aiming to completely remove the tumor through a wide local excision, which involves excising the tumor along with a margin of surrounding healthy tissue to reduce the risk of recurrence. If the cancer has spread to nearby lymph nodes, lymph node dissection is performed. Depending on the location particularly in the oral or nasal areas reconstructive surgery may be necessary to restore function and appearance. Radiation therapy is often used after surgery to destroy any remaining microscopic cancer cells and reduce the risk of recurrence; it can also serve as a primary treatment if surgery is not feasible due to the tumor's location or the patient's health. In more advanced cases, immunotherapy is the standard of care. Drugs known as checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) help activate the immune system to recognize and attack cancer cells; combinations of these drugs are often used for better outcomes. Targeted therapy may be an option if genetic testing reveals a KIT mutation, in which case drugs like imatinib (Gleevec) can be effective. Chemotherapy, once a mainstay of cancer treatment, is now used less frequently for mucosal melanoma due to limited effectiveness but may still be considered if other therapies fail. Overall, the treatment strategy is multidisciplinary and may involve a combination of surgical, medical, and radiation oncology to achieve the best possible outcomes.

The cause of mucosal melanoma is unknown, preventing it is difficult, but certain steps can help reduce the risk. Avoiding tobacco use and excessive alcohol consumption-particularly important for oral mucosal melanoma can minimize exposure to irritants that damage mucous membranes. Managing chronic inflammation in the sinuses or oral cavity through proper medical care may prevent long-term tissue irritation that could contribute to cancer development. Regular dental and ear, nose, and throat (ENT) check-ups are crucial for early detection of abnormal growths, improving treatment outcomes. Additionally, while research is still ongoing, HPV vaccination might help lower the risk by protecting against human papillomavirus infections potentially linked to some cases of mucosal melanoma.

Researchers are actively investigating several promising areas to improve the understanding and treatment of mucosal melanoma. One focus is on developing new immunotherapy combinations aimed at enhancing response rates in advanced cases, seeking to boost the effectiveness of current immune checkpoint inhibitors. Concurrently, genetic research is uncovering molecular targets and mutations unique to mucosal melanoma, which could enable more personalized and targeted treatment approaches. Efforts are also underway to create liquid biopsy tests, which would allow for minimally invasive blood tests to detect mucosal melanoma early and monitor disease progression or treatment response in real time. Additionally, scientists are exploring the development of mucosal melanoma-specific vaccines (MCC vaccines) as a potential preventive strategy, aiming to stimulate the immune system to recognize and attack tumor cells before they develop or progress.

1. Is mucosal melanoma more dangerous than cutaneous melanoma? Yes. It is more aggressive, harder to detect, and often diagnosed at later stages, making it more challenging to treat. 2. Can mucosal melanoma be cured? Early stages may be cured with surgery and radiation, but advanced stages are harder to treat and often require immunotherapy. 3. How rare is mucosal melanoma? It is extremely rare, accounting for only 1% of all melanomas. 4. What are the survival rates for mucosal melanoma? For localized stages, the 5-year survival rate is 50-60%; for advanced stages, it drops to 10-30% due to high recurrence. 5. Can mucosal melanoma recur after treatment? Yes, it has a high recurrence rate, especially in advanced stages, so regular follow-up is essential.